<CPDPDocument>
	<AIDs>
		<AID create="true">
			<Information>
				<Item id="SummaryAID#">2770</Item>
				<Item id="ProjectUID(CARS)"></Item>
				<Item id="AssignedAID#"></Item>
				<Item id="ProjectCategory">MLPCN (Assay Provider)</Item>
				<Item id="CARSHTSStage">tertiary:dose response</Item>
				<Item id="ProbeType">antagonist</Item>
				<Item id="DescriptiveName(AIDtitle)">Luminescence-based cell-based primary high throughput screening assay to identify antagonists of COUP-TFII (NR2F2)</Item>
				<Item id="ShortName">COUPTFII_INH_LUMI_1536_3XIC50 DRUN</Item>
				<Item id="AssayCenter">The Scripps Research Institute Molecular Screening Center</Item>
				<Item id="PhenotypicScreen">no</Item>
				<Item id="Multiplexing">no</Item>
				<Item id="BSL">bsl 2</Item>
				<Item id="CompoundScreeningConcentration">50</Item>
				<Item id="ConcentrationUnits">concentration unit:uM</Item>
				<Item id="#ConcentrationPoints">10</Item>
				<Item id="#DilutionFactor">1:2</Item>
				<Item id="#Replicates">3</Item>
				<Item id="AssayFormat">Cell based: Lysed Cell</Item>
				<Item id="CellLine">293</Item>
				<Item id="AssayType">signal transduction assay:reporter-gene assay</Item>
				<Item id="AssayMethod">End-point Assay</Item>
				<Item id="ResultType">concentration endpoint:concentration response endpoint:IC50</Item>
				<Item id="AssayReadoutContent">single parameter</Item>
				<Item id="AssayReadoutType">measured value</Item>
				<Item id="TargetType">Nuclear Receptors</Item>
				<Item id="TargetDescription">single target</Item>
				<Item id="AssayDetection">Luminescence Other</Item>
				<Item id="SignalDirection">signal decrease:signal decrease corresponding to inhibition</Item>
				<Item id="AssayDetectionMethodType">luminescence method:chemiluminescence</Item>
				<Item id="AssayDetectionInstrument">PerkinElmer ViewLux</Item>
				<Item id="ExcitationWavelength"></Item>
				<Item id="EmissionWavelength"></Item>
				<Item id="AbsorbanceWavelength"></Item>
				<Item id="UsedforHitValidation?">yes</Item>
				<Item id="UsedforSAR?">yes</Item>
				<Item id="ImplementationStartDate"></Item>
				<Item id="ValidationStartDate"></Item>
				<Item id="CriticalReagents">HEK-293T cells, pcDNA6.2-COUP-TFII, pXP2-168</Item>
				<Item id="Consumables">Assay plates (PerkinElmer #6007688)
OptiMEM (Invitrogen #11058021)
X-tremeGENE 9 (Roche Applied Science #06365809001)
DMEM (Mediatech Inc. #10-013-CV)
BriteLite (PerkinElmer #6007688)</Item>
				<Item id="Description-AssayPurpose">The purpose of this cell-based assay is to identify compounds that can inhibit COUP-TFII transcriptional activity. The expression vectors for COUP-TFII p(cDNA6.2-COUP-TFII) and the luciferase reporter NGFI-A-Luc (pXP2-168) are transiently cotransfected into HEK-293T cells. COUP-TFII has been shown to efficiently activate NGFI-A-Luc expression (17) and the readout can be measured by a luminometer. Small molecules that inhibit COUP-TFII transcriptional activity will decrease the promoter activity that can be detected by luciferase assay. As designed, compounds that inhibit COUP-TFII activity will decrease luciferase activity, resulting in decreased well luminescence.</Item>
				<Item id="Description-DetailedProtocols">On Day 1, Transfection mix: In 600 ul of Opti-Mem (invitrogen#11058021), add 27 ul of X-tremeGENE9 (Roche Applied Science, part 06365809001). Incubate for 5 min.Add 9 ug total DNA (4.5 ug pXP2-168 + 4.5 ug pcDNA6.2-COUP-TFII /pcDNA6.2-CAT) to the above mix. Mix it gently and let the mixture sit for at least 20 minutes. During the 2nd incubation of 20 minutes, harvest cells from a 15 cm dish as follows:
a) Remove media via vacuum aspiration completely.
b) Add 1 ml trypsin-EDTA to the cells and evenly spread over plate.
c) Bang the plate with the palm of your hand to dislodge cells from the surface of the plate.
d) Allow cells to sit in the tissue culture hood for 3-5 minutes.
e) Add 10 ml of 37 C full medium to the plate of cells.
f) Pipet up and down 10-15 times with a 10 ml pipet until a single cell suspension is obtained. Try to avoid creating too much froth.
g) Count cells in a hemocytometer.
Mix 8.5 ml of medium containing 3 x 106 cells with transfection mix in 10 cm dish and incubate for overnight in the CO2 incubator. On Day 2, In the morning, harvest the cells as above (0.5 ml trypsin-EDTA) in 10 ml of medium and count them. Seed 10,000 cells per 384 well in 20 ul of medium. In the afternoon (4 hr after seeding), treat with the compounds diluted in medium (20 ul). On Day 3, Develop with Luciferase reagent by adding 30 ul of Britelite Plus (after 16-20 hr of compound treatment).</Item>
				<Item id="CalculationSummary"></Item>
				<Item id="Curve-fitequation"></Item>
				<Item id="Keywords">PRUN, primary, HTS, nuclear hormone receptor, NHR, reporter assay, luciferase, LUMI, COUPTFII, chicken ovalbumin upstream promoter, COUP transcription factor 2, NR2F2, ARP1, COUPTFB, NF-E3, NR2F1, SVP40, TFCOUP2, 1536, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN</Item>
				<Item id="Comments"></Item>
				<Item id="AssayCut-offNumber">10</Item>
				<Item id="AssayCut-offQualifier">&gt;</Item>
				<Item id="AssayCut-offUnits">unit:concentration unit:unit of molarity:microM</Item>
				<Item id="Est.StartDate"></Item>
				<Item id="Est.Throughput"></Item>
				<Item id="HoldUntilDate"></Item>
			</Information>
			<Targets>
				<Target>
					<Item id="TargetType">protein</Item>
					<Item id="NCBITargetGeneName">NR2F2 nuclear receptor subfamily 2, group F, member 2 [ Homo sapiens]</Item>
					<Item id="NCBITargetGeneID#">7026</Item>
					<Item id="NCBITargetProteinName">COUP transcription factor 2</Item>
					<Item id="NCBITargetProteinID#">9629429</Item>
					<Item id="NCBITargetTaxonomyName">Homo sapiens</Item>
					<Item id="NCBITargetTaxonomyID#">9606</Item>
					<Item id="NCBITargetOMIMName">NUCLEAR RECEPTOR SUBFAMILY 2, GROUP F, MEMBER 2; NR2F2</Item>
					<Item id="NCBITargetOMIM#">107773</Item>
				</Target>
			</Targets>
		</AID>
	</AIDs>
	<Project>
		<Information>
			<Item id="ProjectTitlePhysiological"> Mechanism of Action of COUP-Transcription Factors
			</Item>
			<Item id="GrantApplicationNumber"> R01DK45641 </Item>
			<Item id="SubmitterInstitution"> Baylor College of Medicine </Item>
			<Item id="ScreeningCenterName">The Scripps Research Institute Molecular Screening Center</Item>
			<Item id="ChemistryCenterName">The Scripps Research Institute Molecular Screening Center</Item>
			<Item id="DateProjectAssigned(CARSStartDate)">12/10/2012</Item>
			<Item id="CPDPKickoffTeleconferenceDate">1/17/2013</Item>
			<Item id="CPDPChemistryUpdateDateTeleconferenceDate"></Item>
			<Item id="CPDPTypeChemistry"></Item>
			<Item id="RevisionNo."></Item>
		</Information>
		<Contacts>
			<Contact id="ScreeningCenterPI">
				<Name>Hugh Rosen</Name>
				<Email>hrosen@scripps.edu</Email>
				<Phone>858-784-2396</Phone>
			</Contact>
			<Contact id="ScreeningCenterManager">
				<Name>Peter Hodder</Name>
				<Email>hodderp@scripps.edu</Email>
				<Phone>561-228-2100</Phone>
			</Contact>
			<Contact id="ScreeningLead">
				<Name>Franck Madoux </Name>
				<Email>fmadoux@scripps.edu</Email>
				<Phone>561-228-2149 </Phone>
			</Contact>
			<Contact id="ChemistryCenterPI">
				<Name>Hugh Rosen </Name>
				<Email>hrosen@scripps.edu </Email>
				<Phone>858-784-2396 </Phone>
			</Contact>
			<Contact id="ChemistryCenterManager">
				<Name>William Roush </Name>
				<Email>roush@scripps.edu </Email>
				<Phone>561-228-2450 </Phone>
			</Contact>
			<Contact id="ChemistryLead">
				<Name>Click here to enter text.</Name>
				<Email>Click here to enter text.</Email>
				<Phone>Click here to enter text.</Phone>
			</Contact>
			<Contact id="TechnicalWriter/CARSManager">
				<Name>Jill Ferguson </Name>
				<Email>jillferg@scripps.edu </Email>
				<Phone>858-784-8821 </Phone>
			</Contact>
			<Contact id="AssayProvider">
				<Name>Ming-Jer Tsai </Name>
				<Email>mtsai@bcm.edu </Email>
				<Phone>713-798-6253 </Phone>
			</Contact>
			<Contact id="NIHScienceOfficer">
				<Name>Ron Margolis (NIDDK) </Name>
				<Email>margolisr@mail.nih.gov </Email>
				<Phone>301-594-8819 </Phone>
			</Contact>
		</Contacts>
	</Project>
	<ProjectDescription>
		<Paragraph>Steroid receptor chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) (1), an orphan nuclear receptor and member of the nuclear receptor superfamily, has been shown to be a critical transcriptional regulator in many different cancer types by promoting angiogenesis (2-4), cell proliferation and metastasis (5-11). COUP-TFII has widespread tissue distribution in human; detectable expression has been found in every tissue type examined (12). Currently, the treatment for tumor angiogenesis focuses mainly on blocking VEGFR-2 signaling and has not been effective due to limited efficacy, eventually leading to resistance and/or relapse. COUP-TFII has been shown to promote tumor angiogenesis through modulating multiple angiogenic signals (VEGF/VEGFR-2, Angiopoietin 1/Tie2 and E2F-1) in many different types of cancer (13-14). In addition, COUP-TFII is overexpressed in prostate and several other cancers and is an excellent prognostic marker. By including COUP-TFII data with Cyclin D1, p21, PTEN, and Smad4 data in the prognosis, the prognostic accuracy is improved. The expression level of COUP-TFII and its role in regulating tumor growth and metastasis in prostate cancer has been examined, and these data indicate that COUP-TFII positively promotes prostate tumor growth and metastasis (15). These results provide the rational basis to posit that inhibition of COUP-TFII may offer a novel and broadly efficacious approach for anticancer intervention.</Paragraph>
		<Paragraph>COUP-TFII has also been shown to regulate energy storage and expenditure. We have found that COUP-TFII heterozygous mice have increased mitochondrial biogenesis in white adipose tissue, which results in higher energy expenditure, resulting in resistance to high fat diet-induced obesity and improved glucose homeostasis due to increased insulin sensitivity at peripheral tissues (16). These results indicate that COUP-TFII has an important role in regulating adipocyte differentiation and energy metabolism. Therefore, COUP-TFII inhibitors could potentially serve as agents to improve insulin sensitivity, enhance energy metabolism, and decrease high fat diet-induced obesity.</Paragraph>
	</ProjectDescription>
	<References>
		<Reference>
			<Text>1. Sagami, I., Tsai, S. Y., Wang, H., Tsai, M. J., and O'Malley, B. W. (1986) Identification of two factors required for transcription of the ovalbumin gene, Mol Cell Biol 6, 4259-4267.</Text>
			<PMID>3796602</PMID>
		</Reference>
	</References>
</CPDPDocument>
